Concepedia

Filip Dumitru

FD

Statistics

Publications

3

Citations

2.3K

H-Index

3

Active since

2013

Affiliations

Eli Lilly (United States)(Current)

Dana-Farber Cancer Institute

Brown University

Royal Marsden Hospital

Masaryk Memorial Cancer Institute

Filip Dumitru is an author at Eli Lilly (United States) specializing in cancer immunotherapy, medicine, and gastrointestinal oncology.

Publications per year

2013–2016

3

Publications

3

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Charles S. Fuchs, Jiří Tomášek, Filip Dumitru et al. · The Lancet · 2013 · 2.2K citations · Full text

, , +12

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

Charles S. Fuchs, Josep Tabernero, Jiří Tomášek et al. · British Journal of Cancer · 2016 · 69 citations · Full text

, , +17

REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.

Charles S. Fuchs, Jiří Tomášek, Filip Dumitru et al. · Journal of Clinical Oncology · 2013 · 42 citations

, , +16

1–3 of 3